Home

Evidence-Based Treatment Strategies for Tardive Dyskinesia

CME

Friday, June 13, 2025 | 12:00 PM - 12:30 PM TZ

Supported by an independent educational grant from Teva Pharmaceuticals.

overview

Tardive dyskinesia (TD) is a persistent and potentially disabling movement disorder associated with the use of antipsychotic medications. The involuntary and repetitive facial movements that occur with TD often result in unwanted attention, feelings of embarrassment, and a fear of rejection, negatively impacting quality of life and overall mental well-being. Early treatment of TD can potentially lead to better outcomes and even symptom remission. The second program in this series of 3 webinars will discuss guideline recommendations for the management of TD, mechanism of action of evidence-based treatments for TD, and the efficacy and safety profiles of FDA-approved treatments for TD.

Enhance Your Experience With MedChallenge!

This event features MedChallenge, a new feature from Medscape that allows you to go head-to-head against your peers in a series of medical questions. Earn points, deepen your knowledge, and fight for the top spot on the leaderboard!

faculty

Leslie Citrome, MD, MPH

Clinical Professor, Psychiatry and Behavioral Sciences

New York Medical College

Valhalla, New York

AGENDA

12:00 PM TZ

Guideline Recommendations for the Management of TD

12:05 PM TZ

Mechanism of Action of Evidence-Based Treatments for TD

12:10 PM TZ

Clinical Efficacy of FDA-Approved Treatments for TD

12:20 PM TZ

Safety Profile of FDA-Approved Treatments for TD

12:25 PM TZ

Q&A

Enhance Your Virtual Experience With Backstage Pass! Backstage Pass provides an intimate virtual session where you can interact with faculty, address case-based questions, and facilitate relationship building.

*Video encouraged*

TARGET AUDIENCE

This educational activity is intended for an audience of psychiatrists, neurologists, nurse practitioners/physician assistants, and primary care physicians in the United States.

GOAL STATEMENT

The goal of this activity is for learners to be better able to recognize the signs and symptoms of tardive dyskinesia (TD) and select evidence-based treatment strategies.

LEARNING OBJECTIVES

[bold]Upon completion of this activity, participants will:[/bold] [para]Have increased knowledge regarding the:[/para] [list][item]Evidence supporting FDA-approved treatments for TD, including vesicular monoamine transporter type 2 (VMAT2) inhibitors [item]Mechanisms of action and safety profiles of current TD therapies [/list] [para]Have greater competence related to:[/para] [list][item]Applying evidence-based guidelines to select optimal treatments based on patient needs [/list]

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

[title]For Physicians[/title] [text]Medscape, LLC designates this live activity for a maximum of 0.50 [bold][italic]AMA PRA Category 1 Credit(s)[/italic][super]TM[/super][/bold]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.[/text]